Entest Biomedical, Inc. announced that the company's recent research study conducted on ImenVax(TM) (Entest's Immuno-therapeutic cancer vaccine for dogs), ImenVax(TM) appears to show signs of slowing tumor growth in advanced cases of oral melanoma, while being well tolerated by patients. The company's researchers stated that subjectively, tumor progression was slowed during the period that the implant was present and accelerated after removal in 2 patients. The report recommends that further evaluation in patients with lesser tumor burden is warranted, along with cytokine stimulation.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | -.--% | -.--% | -.--% |
2020 | Entest Group, Inc. Reports Earnings Results for the First Quarter Ended November 30, 2019 | CI |
2019 | Entest Group, Inc. Reports Earnings Results for the Full Year Ended August 31, 2019 | CI |
1st Jan change | Capi. | |
---|---|---|
-.--% | 4.92K | |
+191.37% | 6.97B | |
+5.09% | 1.04B | |
+2.10% | 982M | |
+41.91% | 872M | |
+24.45% | 814M | |
+11.31% | 675M | |
+1.72% | 664M | |
+0.00% | 600M | |
+3.61% | 503M |
- Stock Market
- Equities
- ETNI Stock
- News Entest Group, Inc.
- Entest Biomedical, Inc. Announces the Research Study Conducted on ImenVax(TM)